Journal
SEMINARS IN IMMUNOLOGY
Volume 31, Issue -, Pages 55-63Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2017.08.003
Keywords
NK cells; Innate lymphoid cells (ILC); Cancer; Immune checkpoint inhibitors (ICI); Immunoreceptor tyrosyne-based inhibitory motif (ITIM)
Categories
Funding
- European Research Council advanced grant
- Agence Nationale de la Recherche
- Ligue Nationale contre le Cancer (Equipe labellisee La Ligue)
- INSERM
- CNRS
- Aix-Marseille University
- Marseille Immunopole
Ask authors/readers for more resources
After many years of research, recent advances have shed new light on the role of the immune system in advanced-stage cancer. Various types of immune cells may be useful for therapeutic purposes, along with chemical molecules and engineered monoclonal antibodies. The immune effectors suitable for manipulation for adoptive transfer or drug targeting in vivo include natural killer (NK) cells. These cells are of particular interest because they are tightly regulated by an array of inhibitory and activating receptors, enabling them to kill tumor cells while sparing normal cells. New therapeutic antibodies blocking the interactions of inhibitory receptors (immune checkpoint inhibitors, ICI) with their ligands have been developed and can potentiate NK cell functions in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available